The 340B PATIENTS Act clarifies and strengthens protections under the existing 340B drug discount program, which allows hospitals, clinics, and health centers to purchase medications at reduced prices from manufacturers. The bill specifically ensures that drug manufacturers cannot restrict how or where covered entities dispense these discounted drugs, including through contracts with pharmacies, and prohibits manufacturers from imposing conditions that would undermine the program's goals. The legislation applies to specialty drugs used for serious conditions like cancer and rheumatoid arthritis, which covered entities often can only access through contract pharmacy arrangements located far from their facilities. To enforce these protections, the bill establishes civil penalties of up to $2 million per day for manufacturers that violate these requirements and requires the Department of Health and Human Services to create enforcement regulations within 180 days of enactment. This act aims to preserve the program's original purpose of allowing healthcare providers to stretch limited resources to serve more patients and provide comprehensive community care.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.